AU2001214087A1 - Anticancer compound and enantiomer separation method useful for synthesizing said compound - Google Patents
Anticancer compound and enantiomer separation method useful for synthesizing said compoundInfo
- Publication number
- AU2001214087A1 AU2001214087A1 AU2001214087A AU1408701A AU2001214087A1 AU 2001214087 A1 AU2001214087 A1 AU 2001214087A1 AU 2001214087 A AU2001214087 A AU 2001214087A AU 1408701 A AU1408701 A AU 1408701A AU 2001214087 A1 AU2001214087 A1 AU 2001214087A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- synthesizing
- separation method
- method useful
- enantiomer separation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 230000001093 anti-cancer Effects 0.000 title 1
- 238000000926 separation method Methods 0.000 title 1
- 230000002194 synthesizing effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17771800P | 2000-01-21 | 2000-01-21 | |
US60177718 | 2000-01-21 | ||
PCT/IB2000/001769 WO2001053289A1 (en) | 2000-01-21 | 2000-11-29 | Anticancer compound and enantiomer separation method useful for synthesizing said compound |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001214087A1 true AU2001214087A1 (en) | 2001-07-31 |
Family
ID=22649709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001214087A Abandoned AU2001214087A1 (en) | 2000-01-21 | 2000-11-29 | Anticancer compound and enantiomer separation method useful for synthesizing said compound |
Country Status (17)
Country | Link |
---|---|
US (1) | US6479513B2 (en) |
EP (1) | EP1248782A1 (en) |
JP (2) | JP2003520796A (en) |
AR (1) | AR029792A1 (en) |
AU (1) | AU2001214087A1 (en) |
BR (1) | BR0016986A (en) |
CA (1) | CA2398353C (en) |
CO (1) | CO5271702A1 (en) |
GT (1) | GT200100008A (en) |
HN (1) | HN2000000266A (en) |
MX (1) | MXPA02007153A (en) |
MY (1) | MY126069A (en) |
PA (1) | PA8508101A1 (en) |
PE (1) | PE20011118A1 (en) |
SV (1) | SV2002000291A (en) |
TN (1) | TNSN01009A1 (en) |
WO (1) | WO2001053289A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HN2000000266A (en) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | ANTI-TARGET COMPOUND AND METHOD OF SEPARATION OF ENANTIOMERS USEFUL TO SYNTHEIZE SUCH COMPOUND. |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Farnesyl transferase inhibiting 1-2 annelated quinoline enantiomer |
ATE434615T1 (en) | 2000-11-21 | 2009-07-15 | Janssen Pharmaceutica Nv | FARNESYLTRANSFERASE INHIBITING BENZOHETROCYCLIC DERIVATIVES |
ES2260316T3 (en) | 2000-12-27 | 2006-11-01 | Janssen Pharmaceutica N.V. | DERIVATIVES OF QUINAZOLINA AND QUINOLINA 4-SUBSTITUTES THAT INHIBIT THE FARNESIL TRANSFERASA. |
WO2003006006A1 (en) * | 2001-07-09 | 2003-01-23 | The Regents Of The University Of California | Use of matrix metalloproteinase inhibitors to mitigate nerve damage |
EP1458720B1 (en) | 2001-12-19 | 2009-03-18 | Janssen Pharmaceutica N.V. | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
WO2003080058A1 (en) | 2002-03-22 | 2003-10-02 | Janssen Pharmaceutica. N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
ES2271574T3 (en) | 2002-04-15 | 2007-04-16 | Janssen Pharmaceutica N.V. | INHIBITING TRICYCLINE DERIVATIVES OF FARMESILTRANSFERASA INHIBITORS, REPLACED WITH IMIDAZOLES OR TRIAZOLS LINKED TO CARBON. |
CA2510850A1 (en) * | 2002-12-19 | 2004-07-08 | Pfizer Inc. | 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
CA2561516A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
DE602005007604D1 (en) | 2004-05-03 | 2008-07-31 | Janssen Pharmaceutica Nv | DIASTEREOSELECTIVE ADDITION OF LITHIATED N-METHYLIMIDAZOLE ON SULFINIMINES |
WO2005105784A1 (en) * | 2004-05-03 | 2005-11-10 | Janssen Pharmaceutica N.V. | Diastereoselective synthesis process for the preparation of imidazole compounds |
ES2346986T3 (en) | 2004-05-03 | 2010-10-22 | Janssen Pharmaceutica Nv | DIASTEREOSELECTIVE SYNTHESIS PROCESS WITH 6-BROMO-4- (3-CHLOROPHENYL) -2-METHOXI-QUINOLINA. |
MX2007001986A (en) * | 2004-08-26 | 2007-05-10 | Pfizer | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors. |
CA2578066C (en) | 2004-08-26 | 2011-10-11 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
WO2006021881A2 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
US20060107555A1 (en) * | 2004-11-09 | 2006-05-25 | Curtis Marc D | Universal snow plow adapter |
WO2007035744A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2545919A1 (en) | 2005-12-23 | 2013-01-16 | Link Medicine Corporation | Treatment of synucleinopathies |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
AR062419A1 (en) | 2006-08-21 | 2008-11-05 | Hoffmann La Roche | TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
WO2010057006A1 (en) | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2542893A2 (en) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
AR094403A1 (en) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | ANTI-HER3 ANTIBODY COMBINATION THERAPY |
CA3006743A1 (en) | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
TR199800825T2 (en) * | 1995-12-08 | 1998-08-21 | Janssen Pharmaceutica N.V. | Methyl-2-quinolinone derivatives that inhibit farnesyl protein transfer (imidazol-5-yl). |
CA2341690C (en) | 1998-08-27 | 2007-04-17 | Pfizer Products Inc. | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents |
CZ20012910A3 (en) * | 1999-02-11 | 2002-02-13 | Pfizer Products Inc. | Heteroaryl-substituted quinolin-2-one derivatives usable as antitumor preparations |
HN2000000266A (en) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | ANTI-TARGET COMPOUND AND METHOD OF SEPARATION OF ENANTIOMERS USEFUL TO SYNTHEIZE SUCH COMPOUND. |
-
2000
- 2000-11-27 HN HN2000000266A patent/HN2000000266A/en unknown
- 2000-11-29 MX MXPA02007153A patent/MXPA02007153A/en active IP Right Grant
- 2000-11-29 JP JP2001553763A patent/JP2003520796A/en active Pending
- 2000-11-29 AU AU2001214087A patent/AU2001214087A1/en not_active Abandoned
- 2000-11-29 BR BR0016986-2A patent/BR0016986A/en not_active Application Discontinuation
- 2000-11-29 WO PCT/IB2000/001769 patent/WO2001053289A1/en not_active Application Discontinuation
- 2000-11-29 EP EP00976213A patent/EP1248782A1/en not_active Withdrawn
- 2000-11-29 CA CA002398353A patent/CA2398353C/en not_active Expired - Fee Related
- 2000-12-04 PA PA20008508101A patent/PA8508101A1/en unknown
- 2000-12-27 CO CO00097877A patent/CO5271702A1/en not_active Application Discontinuation
-
2001
- 2001-01-17 PE PE2001000041A patent/PE20011118A1/en not_active Application Discontinuation
- 2001-01-17 US US09/761,994 patent/US6479513B2/en not_active Expired - Fee Related
- 2001-01-18 GT GT200100008A patent/GT200100008A/en unknown
- 2001-01-18 AR ARP010100227A patent/AR029792A1/en unknown
- 2001-01-19 MY MYPI20010243A patent/MY126069A/en unknown
- 2001-01-19 TN TNTNSN01009A patent/TNSN01009A1/en unknown
- 2001-01-22 SV SV2001000291A patent/SV2002000291A/en not_active Application Discontinuation
-
2007
- 2007-07-18 JP JP2007186597A patent/JP2007326868A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20011118A1 (en) | 2001-11-06 |
MXPA02007153A (en) | 2002-12-13 |
WO2001053289A1 (en) | 2001-07-26 |
US6479513B2 (en) | 2002-11-12 |
CO5271702A1 (en) | 2003-04-30 |
CA2398353C (en) | 2007-07-31 |
BR0016986A (en) | 2002-10-08 |
HN2000000266A (en) | 2001-05-21 |
CA2398353A1 (en) | 2001-07-26 |
EP1248782A1 (en) | 2002-10-16 |
US20020004514A1 (en) | 2002-01-10 |
GT200100008A (en) | 2001-10-19 |
SV2002000291A (en) | 2002-07-16 |
TNSN01009A1 (en) | 2005-11-10 |
JP2007326868A (en) | 2007-12-20 |
MY126069A (en) | 2006-09-29 |
AR029792A1 (en) | 2003-07-16 |
JP2003520796A (en) | 2003-07-08 |
PA8508101A1 (en) | 2002-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001214087A1 (en) | Anticancer compound and enantiomer separation method useful for synthesizing said compound | |
AU2001267740A1 (en) | Separation method | |
AU2001240115A1 (en) | Method for the preparation of tetrahydrobenzothiepines | |
AU2002224154A1 (en) | Method for producing polybutene | |
AU2002237527A1 (en) | Method of synthesizing camptothecin-relating compounds | |
AU2001284697A1 (en) | Method of synthesizing diketopiperazines | |
AU6707400A (en) | Process for separating metals | |
AU2001239243A1 (en) | Method for producing nanosuspensions | |
AU2001291882A1 (en) | Method for producing polyisobutylphenols | |
AU2001230207A1 (en) | Method for the production of 1-amino-3-aryl-uracils | |
AU2825400A (en) | Two-dimensional separating method | |
AU2002218171A1 (en) | Method for producing aryl compounds | |
EP1298117A3 (en) | Method for preparing bromofluorenes | |
AU2001213451A1 (en) | Method for preparation of polycarbonates | |
AU2002224842A1 (en) | Method for binding compound elements | |
AU2002231187A1 (en) | Method for synthesizing diamond | |
AU7432700A (en) | Separation method | |
AU2001290260A1 (en) | Process for producing fluoroamine compound | |
AU2001267641A1 (en) | Method for separating a hydroxybenzonitrile-type compound | |
AU2002212224A1 (en) | Method for producing delta1-pyrrolines | |
AU3161701A (en) | Method for producing nitroguanidine | |
AU1283001A (en) | Method for producing alkylhalogenosilanes | |
AU4856501A (en) | Screening method for compounds | |
AU2001262147A1 (en) | Method for producing 4-bromo- and 4-chloro-2-nitro-1-trifluoromethoxybenzene | |
AU2001231676A1 (en) | Substituted phenylamidines medicaments containing said compounds and method for production thereof |